Download Image
    
Share
  
Post
GPAT for COVID-19
1 study with 243 patients
Hospital Icon Control
Hospital Icon GPAT Serious Outcome Risk
COVID-19 GPAT studies. May 2026. c19early.org
0 0.5 1 1.5+ All studies -38% Hospitalization -38% RCTs -38% Early -38% FavorsGPAT Favorscontrol
Graphene photothermal adjuvant therapy (GPAT) is a device-based physical intervention that utilizes a graphene electrothermal film to deliver far-infrared radiation, investigated for its potential to modulate inflammatory immune response.
Apr 28
 An et al., Scientific Reports, doi:10.1038/s41598-026-50266-y Effects of graphene photothermal adjuvant therapy in patients infected with the Omicron BF.7 variant 2022: a prospective randomized controlled trial
38% higher hospitalization (p=0.02) and 35% worse recovery (p=0.03). RCT 243 mildly symptomatic hospitalized COVID-19 patients (Omicron BF.7 variant) in China showing increased risk with graphene photothermal adjuvant therapy (GPAT). All patients received nebulized N-acetylcysteine and the interaction with..